Sugi Predict

Sugi Predict / Compounds / Diflucortolone 21-Valerate

Diflucortolone 21-Valerate

Diflucortolone 21-Valerate

SCHEMBL679499

CCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C.CCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C.CCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C.CCCCC(=O)OCC(=O)[C@H]1[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C.[S-2].[S-2]

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 8/20 0.72
▸ NR1I2 O75469 3/20 0.72
▸ HTR2B P41595 1/20 0.72
▸ AR P10275 7/20 0.62
▸ HIF1A Q16665 7/20 0.62
▸ CYP3A4 P08684 5/20 0.62
▸ ADORA3 P0DMS8 3/20 0.62
▸ LMNA P02545 2/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ NR3C1 P04150 9/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ NR3C2 P08235 1/20 0.52
▸ CHRM1 P11229 2/20 0.52
▸ ABCB11 O95342 2/20 0.52
▸ ADRA1A P35348 1/20 0.52
▸ MAPT P10636 1/20 0.51
▸ RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diflucortolone 21-Valerate SCHEMBL1021717 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL13157 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL3015 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL2790985 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL11243011 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL9388448 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL13158 0.99 PGR (0.73) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL16338435 0.98 PGR (0.72) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL4454848 0.98 PGR (0.72) PGRNR1I2HTR2BARHIF1A
Diflucortolone 21-Valerate SCHEMBL15312089 0.98 PGR (0.72) PGRNR1I2HTR2BARHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10821211-B2 Coatings and biomedical implants formed from keratin biomaterials WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2020-11-03 — — US disclosed
US-20190143004-A1 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS UNIV WAKE FOREST HEALTH SCIENCES (US) 2019-05-16 — — US disclosed
US-10195314-B2 Fractionation of charged keratin WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2019-02-05 — — US disclosed
EP-1991256-B1 CLOTTING AND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS UNIV WAKE FOREST HEALTH SCIENCES (US) 2016-11-23 — — EP disclosed
US-20150367043-A1 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS UNIV WAKE FOREST HEALTH SCIENCES (US) 2015-12-24 — — US disclosed
US-9149566-B2 Coatings and biomedical implants formed from keratin biomaterials WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2015-10-06 — — US disclosed
US-9068162-B2 Keratin biomaterials for cell culture and methods of use WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2015-06-30 — — US disclosed
EP-1983927-B1 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS UNIV WAKE FOREST HEALTH SCIENCES (US) 2014-11-05 — — EP disclosed
US-8637231-B2 Method for increasing the volume of a blood substitute with an expander comprising basic alpha keratose WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2014-01-28 — — US disclosed
US-8299013-B2 Clotting and healing compositions containing keratin biomaterials WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2012-10-30 — — US disclosed
US-20090004242-A1 Coatings and Biomedical Implants Formed From Keratin Biomaterials SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-01-01 — — US disclosed
EP-1991256-A2 CLOTTING AND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS Wake Forest University Health Sciences (US) 2008-11-19 — — EP disclosed
US-20080274165-A1 WOUND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS WAKE FOREST UNIVERSITY HEALTH SCIENCES 2008-11-06 — — US disclosed
WO-2008130607-A2 WOUND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2008-10-30 — — WO disclosed
EP-1983927-A2 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS Wake Forest University Health Sciences (US) 2008-10-29 — — EP disclosed
US-7439012-B2 Blood substitutes; basic alpha keratose produced via ion exchange chromatography, and gamma keratose solubilized in an electrolyte solution; given pH, osmolarity, viscosity; shelf-life WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2008-10-21 — — US disclosed
WO-2007098053-A2 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2007-08-30 — — WO disclosed
WO-2007098114-A2 CLOTTING AND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2007-08-30 — — WO disclosed
WO-2007001339-A2 AMBIENT STORED BLOOD PLASMA EXPANDERS WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2007-01-04 — — WO disclosed
US-20060051732-A1 Blood substitutes; basic alpha keratose produced via ion exchange chromatography, and gamma keratose solubilized in an electrolyte solution; given pH, osmolarity, viscosity; shelf-life US ARMY, SECRETARY OF THE ARMY 2006-03-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090004242-A1 Coatings and Biomedical Implants Formed From Keratin Biomaterials KRT18, KLKB1, F2 PGR 997/4885NR1I2 3423/4885HTR2B 4611/4885
US-20080274165-A1 WOUND HEALING COMPOSITIONS CONTAINING KERATIN BIOMATERIALS KRT18, KLK6, PROC PGR 2503/4885NR1I2 4245/4885HTR2B 4682/4885
US-10821211-B2 Coatings and biomedical implants formed from keratin biomaterials KRT18, KLKB1, F2 PGR 997/4885NR1I2 3423/4885HTR2B 4611/4885
US-20150367043-A1 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS KRT18, KLKB1, F2 PGR 997/4885NR1I2 3423/4885HTR2B 4611/4885
US-20190143004-A1 COATINGS AND BIOMEDICAL IMPLANTS FORMED FROM KERATIN BIOMATERIALS KRT18, KLKB1, F2 PGR 997/4885NR1I2 3423/4885HTR2B 4611/4885
US-20060051732-A1 Blood substitutes; basic alpha keratose produced via ion exchange chromatography, and gamma keratose solubilized in an electrolyte solution; given pH, osmolarity, viscosity; shelf-life KRT18, KLKB1, FUCA2 PGR 4232/4885NR1I2 4215/4885HTR2B 4873/4885
US-10195314-B2 Fractionation of charged keratin KRT18, F2, F12 PGR 2090/4885NR1I2 3486/4885HTR2B 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback